Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited (GUJTHEM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
gtbl.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-04
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 38 Cr | 36 Cr | 42 Cr | 43 Cr | 44 Cr |
| Operating expenses (approx.) | 22 Cr | 22 Cr | 21 Cr | 22 Cr | 23 Cr |
| EBITDA | 16 Cr | 14 Cr | 21 Cr | 21 Cr | 21 Cr |
| OPM % | 42.5% | 38.8% | 49.5% | 49.1% | 47.5% |
| Other income | 1 Cr | 0.27 Cr | 0.82 Cr | 0.42 Cr | 0.13 Cr |
| Interest | 0.07 Cr | 0.04 Cr | 0.04 Cr | 0.96 Cr | 2 Cr |
| Depreciation | 1 Cr | 2 Cr | 3 Cr | 4 Cr | 4 Cr |
| Profit before tax | 16 Cr | 12 Cr | 19 Cr | 17 Cr | 15 Cr |
| Tax % | 25.4% | 25.2% | 24.0% | 26.1% | 27.0% |
| Net profit | 12 Cr | 9 Cr | 14 Cr | 12 Cr | 11 Cr |
| EPS (₹) | ₹1.10 | ₹0.83 | ₹1.31 | ₹1.14 | ₹1.02 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 151 Cr | Sign in for TTM |
| Operating expenses (approx.) | 82 Cr | Sign in for TTM |
| EBITDA | 69 Cr | Sign in for TTM |
| OPM % | 45.7% | Sign in for TTM |
| Other income | 2 Cr | Sign in for TTM |
| Interest | 0.36 Cr | Sign in for TTM |
| Depreciation | 5 Cr | Sign in for TTM |
| Profit before tax | 66 Cr | Sign in for TTM |
| Tax % | 25.6% | Sign in for TTM |
| Net profit | 49 Cr | Sign in for TTM |
| EPS (₹) | ₹4.48 | Sign in for TTM |
| Dividend payout % | 3.7% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 11 Cr |
| Reserves | 237 Cr |
| Borrowings | 30 Cr |
| Other liabilities | 23 Cr |
| Total liabilities | 301 Cr |
| Fixed assets (net) | 41 Cr |
| CWIP | 184 Cr |
| Investments | 0 Cr |
| Inventories | 5 Cr |
| Trade receivables | 31 Cr |
| Cash & bank | 12 Cr |
| Other assets | 28 Cr |
| Total assets | 301 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 91 Cr |
| Cash from investing | -112 Cr |
| Cash from financing | 26 Cr |
| Net cash flow | 5 Cr |
| Free cash flow (OCF − Capex) | -25 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 23.7% |
| ROE % | 19.6% |
| Debtor days | 75 |
| Inventory days | 71 |
| Days payable | 207 |
| Cash conversion cycle | -60 |
| Debt / equity | 0.12 |
| Current ratio | 2.53 |
| Net debt / EBITDA | 0.26 |
Compare with peers
Loading peers…